Etizolam is a thienodiazepine derivative, structurally and pharmacologically similar to benzodiazepines. It is a potent, short-acting anxiolytic, sedative, and hypnotic agent. It acts as a positive allosteric modulator at the GABA-A receptor, enhancing the inhibitory effects of GABA in the central nervous system. In India, it is widely prescribed for short-term management of anxiety and insomnia, but carries significant risks of dependence, tolerance, and withdrawal.
Adult: Anxiety: 0.25 mg to 0.5 mg two to three times daily. Insomnia: 0.5 mg to 1 mg at bedtime. Start with the lowest effective dose (0.25mg).
Note: Administer orally with or without food. For insomnia, take immediately before bedtime. Tablets should be swallowed whole with a glass of water. Treatment duration should be as short as possible, generally not exceeding 2-4 weeks, including tapering period.
Etizolam binds to a specific site (the benzodiazepine binding site) on the GABA-A receptor complex, which is a ligand-gated chloride channel. This binding potentiates the inhibitory effect of the neurotransmitter gamma-aminobutyric acid (GABA), leading to increased frequency of chloride channel opening. The influx of chloride ions hyperpolarizes the neuron, making it less excitable, resulting in central nervous system depression.
Pregnancy: Category D (as per some references). There is positive evidence of human fetal risk. Benzodiazepines may cause fetal harm, including floppy infant syndrome and withdrawal symptoms in the neonate. Should be avoided, especially in the first trimester and near term. Use only if the potential benefit justifies the potential risk to the fetus.
Driving: STRONGLY ADVISED AGAINST. Etizolam impairs alertness, concentration, reaction time, and motor coordination. Patients should not drive or operate heavy machinery until they know how the drug affects them.
| Alcohol | Profound additive CNS and respiratory depression, impaired psychomotor function. | Major |
| Opioids (e.g., Tramadol, Codeine) | Increased risk of profound sedation, respiratory depression, coma, and death. | Major (Black Box Warning in some contexts) |
| Other CNS Depressants (Barbiturates, Antipsychotics, Antihistamines) | Additive CNS depression. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased etizolam plasma levels, leading to enhanced effects and toxicity. | Major |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased etizolam plasma levels, reducing efficacy. | Moderate |
| Sodium Oxybate | Severe CNS depression. | Major |
| Levodopa | Possible reduction in levodopa's efficacy. | Moderate |